Collegium Pharmaceutical (COLL) Competitors $29.69 -0.68 (-2.24%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$29.69 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. CYTK, SRPT, KRYS, ACAD, SWTX, ZLAB, RARE, ACLX, ALVO, and PTGXShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Cytokinetics (CYTK), Sarepta Therapeutics (SRPT), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Alvotech (ALVO), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors Cytokinetics Sarepta Therapeutics Krystal Biotech ACADIA Pharmaceuticals SpringWorks Therapeutics Zai Lab Ultragenyx Pharmaceutical Arcellx Alvotech Protagonist Therapeutics Collegium Pharmaceutical (NASDAQ:COLL) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations. Is COLL or CYTK more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Cytokinetics' net margin of -17,906.25%. Collegium Pharmaceutical's return on equity of 104.67% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Cytokinetics -17,906.25%N/A -50.21% Do analysts prefer COLL or CYTK? Collegium Pharmaceutical presently has a consensus price target of $43.75, indicating a potential upside of 47.36%. Cytokinetics has a consensus price target of $70.92, indicating a potential upside of 114.20%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 Which has higher earnings and valuation, COLL or CYTK? Collegium Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$664.28M1.44$48.15M$1.2224.34Cytokinetics$19.22M205.76-$526.24M-$5.29-6.26 Does the media refer more to COLL or CYTK? In the previous week, Cytokinetics had 13 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 20 mentions for Cytokinetics and 7 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.71 beat Cytokinetics' score of 0.35 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer COLL or CYTK? Cytokinetics received 440 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 79.83% of users gave Cytokinetics an outperform vote while only 65.38% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes39165.38% Underperform Votes20734.62% CytokineticsOutperform Votes83179.83% Underperform Votes21020.17% Which has more risk and volatility, COLL or CYTK? Collegium Pharmaceutical has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. SummaryCollegium Pharmaceutical beats Cytokinetics on 9 of the 17 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$954.00M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio12.808.7827.1120.06Price / Sales1.44255.64409.88157.10Price / Cash2.7665.8538.2534.64Price / Book4.966.557.064.70Net Income$48.15M$143.93M$3.23B$247.88M7 Day Performance0.64%3.97%2.88%2.66%1 Month Performance0.44%11.32%9.04%6.40%1 Year Performance-6.87%4.20%31.40%14.07% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.0333 of 5 stars$29.69-2.2%$43.75+47.4%-8.8%$954.00M$664.28M12.80210Positive NewsInsider TradeCYTKCytokinetics4.4251 of 5 stars$31.21+0.6%$73.71+136.2%-37.9%$3.73B$19.22M-5.80250Trending NewsAnalyst ForecastAnalyst RevisionSRPTSarepta Therapeutics4.8276 of 5 stars$37.74+0.4%$122.61+224.9%-68.8%$3.71B$2.23B30.19840KRYSKrystal Biotech4.6884 of 5 stars$125.36-0.5%$211.13+68.4%-21.3%$3.62B$333.45M41.93210Positive NewsAnalyst RevisionACADACADIA Pharmaceuticals3.242 of 5 stars$21.47-0.5%$26.83+25.0%+48.4%$3.59B$996.28M27.53510Trending NewsAnalyst RevisionSWTXSpringWorks Therapeutics1.6116 of 5 stars$46.67-0.1%$52.57+12.6%+20.1%$3.52B$219.67M-13.41230Positive NewsHigh Trading VolumeZLABZai Lab1.4827 of 5 stars$31.19+3.5%$47.37+51.9%+106.6%$3.44B$418.33M-11.261,950Positive NewsAnalyst RevisionRAREUltragenyx Pharmaceutical4.3634 of 5 stars$36.14+6.2%$88.77+145.6%-9.4%$3.42B$590.69M-5.701,310Analyst RevisionACLXArcellx2.6591 of 5 stars$61.93-0.2%$111.33+79.8%+22.5%$3.41B$76.81M-87.2280Insider TradeAnalyst RevisionALVOAlvotech1.7082 of 5 stars$11.22-1.9%$18.00+60.4%-29.7%$3.38B$585.60M-6.064Short Interest ↑PTGXProtagonist Therapeutics2.0077 of 5 stars$50.15+5.6%$65.44+30.5%+63.0%$3.11B$207.80M18.85120Insider Trade Related Companies and Tools Related Companies CYTK Competitors SRPT Competitors KRYS Competitors ACAD Competitors SWTX Competitors ZLAB Competitors RARE Competitors ACLX Competitors ALVO Competitors PTGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COLL Stock Free COLL Stock Alerts